Is there a current change of maintenance treatment in ovarian cancer? An updated review of the literature

被引：0

作者：

Sakarya, Derya Kilic ^{[1
]}

Yetimalar, Mehmet Hakan ^{[2
]}

机构：

[1] Konya Training & Res Hosp, Dept Obstet & Gynecol, Konya, Turkey

[2] Izmir Katip Celebi Univ, Dept Obstet & Gynecol, Ataturk Training & Res Hosp, Izmir, Turkey

来源：

JOURNAL OF BUON | 2016年 / 21卷 / 02期

关键词：

chemotherapy; maintenance therapy; ovarian cancer; PHASE-III TRIAL; ADVANCED EPITHELIAL OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; RANDOMIZED-TRIAL; STAGE-III; PRIMARY PERITONEAL; COMPLETE RESPONSE; PRIMARY SURGERY; NO EVIDENCE; CHEMOTHERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Maintenance therapy in ovarian cancer has been introduced and evaluated in many large randomized trials; however, its efficacy is still unclear and includes concerns for both short-term and longer-term side effects. Thus far, some therapies that have been studied in this setting showed a delay in tumor progression but unfortunately no improvement in overall survival has been noticed. The introduction of new chemotherapeutic agents redirected research efforts. Assessing benefits of prolonged therapy and its impact in terms of toxicity is considerably important for the decision to administer such treatments. The purpose of this article was to provide an update on the randomized trials and review the role of maintenance therapy in the treatment of ovarian cancer.

引用

页码：290 / 300

页数：11

共 41 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study [J].

Alberts, DS ;

Hannigan, EV ;

Liu, PY ;

Jiang, C ;

Wilczynski, S ;

Copeland, L ;

Markman, M .

GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :133-138

[3] Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group [J].

Alberts, DS ;

Jiang, C ;

Liu, PY ;

Wilczynski, S ;

Markman, M ;

Rothenberg, ML .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (02) :224-228

[4] Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer [J].

Berek, Jonathan ;

Taylor, Peyton ;

McGuire, William ;

Smith, L. Mary ;

Schultes, Birgit ;

Nicodemus, Christopher F. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :418-425

[5] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study [J].

Bolis, G ;

Danese, S ;

Tateo, S ;

Rabaiotti, E ;

D'Agostino, G ;

Merisio, C ;

Scarfone, G ;

Polverino, G ;

Parazzini, F .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :74-78

[6] Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer [J].

Burger, Robert. A. ;

Brady, Mark F. ;

Rhee, Joon ;

Sovak, Mika A. ;

Kong, George ;

Nguyen, Hoa P. ;

Bookman, Michael A. .

GYNECOLOGIC ONCOLOGY, 2013, 131 (01) :21-26

[7] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[8] Overview of anti-angiogenic agents in development for ovarian cancer [J].

Burger, Robert A. .

GYNECOLOGIC ONCOLOGY, 2011, 121 (01) :230-238

[9] Variation in use of palliative resection of primary tumor at first presentation of metastatic colorectal cancer within the New Jersey State Cancer Registry [J].

Chan, Melissa Y. ;

Moore, Dirk ;

Niu, Xiaoling ;

Paddock, Lisa E. ;

Chen, Chunxia ;

Roche, Lisa M. ;

Moss, Rebecca Anne .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[10] Olaparib: a promising PARP inhibitor in ovarian cancer therapy [J].

Chen, Ying ;

Zhang, Lei ;

Hao, Quan .

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) :367-374

← 1 2 3 4 5 →